Merck & Co Inc

默克公司

MRK

默克公司

and

和

Jiangsu Hengrui Pharmaceuticals Co., Ltd

江苏恒瑞制药有限公司

on Tuesday entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2

周二，双方就目前正处于二期临床试验的在研口服小分子脂蛋白(a)或Lp(a)抑制剂HRS-5346签订了独家许可协议。

clinical trial in China

中国的临床试验

.

。

Lipoprotein (a), or Lp(a), is a type of lipoprotein produced in the liver that carries cholesterol, fats, and proteins in the blood.

脂蛋白(a)或Lp(a)是一种由肝脏产生的脂蛋白，它在血液中携带胆固醇、脂肪和蛋白质。

Also Read:

另请阅读：

Pharmaceutical Firms Say UK Investment Is ‘Unlikely’ Unless Payment Levy Is Adressed

制药公司表示，除非支付税得到解决，否则不可能对英国进行投资。

Lp(a) can accumulate in blood vessel walls, forming atherosclerotic plaques similar to LDL cholesterol. These plaques can limit blood flow to vital organs and result in conditions such as heart attack, stroke, and other cardiovascular diseases.

Lp(a) 可以在血管壁中积累，形成类似于低密度脂蛋白胆固醇的动脉粥样硬化斑块。这些斑块会限制重要器官的血液流动，导致心脏病发作、中风和其他心血管疾病等状况。

Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the

根据协议，恒瑞医药已授予默克公司在全球范围内开发、生产和商业化HRS-5346的独家权利，但不包括

Greater China region

大中华地区

.

。

Hengrui Pharma will receive an upfront payment of $200 million and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $1.77 billion and royalties on net sales of HRS-5346 if approved.

恒瑞医药将获得2亿美元的预付款，并有资格获得高达17.7亿美元的与某些开发、监管和商业里程碑相关的里程碑付款，以及HRS-5346获批后的净销售额的特许权使用费。

The transaction is expected to close in the second quarter of 2025.

该交易预计将在2025年第二季度完成。

Merck expects to record a pre-tax charge of $200 million, or approximately $0.06 per share, to be included in GAAP and non-GAAP results in the quarter the transaction closes.

默克预计将在交易完成的季度记录2亿美元的税前费用，约合每股0.06美元，计入GAAP和非GAAP结果。

Price Action:

价格行为:

MRK stock is down 1.82% at $90.63 at the last check Tuesday.

MRK股票在周二最后一次检查时下跌1.82%，至90.63美元。

Read Next:

接下来读：

Shell Unveils New Strategy: Higher Buybacks, Cost Cuts And 10% Annual Free Cash Flow Growth

壳牌公布新战略：更高额回购、削减成本以及10%的年自由现金流增长

Photo: Shutterstock

照片来源：Shutterstock

MRK

默克公司

Merck & Co Inc

默克公司

$89.92

89.92美元

-2.59

-2.59

%

%

Stock Score Locked: Want to See it?

股票评分已锁定：想查看吗？

Benzinga Rankings give you vital metrics on any stock – anytime.

Benzinga 排名为您提供任何股票的关键指标——随时查看。

Reveal Full Score

显示完整分数

Edge Rankings

边缘排名

Momentum

动量

19.51

19.51

Growth

增长

98.12

98.12

Quality

质量

74.64

74.64

Value

值

15.36

15.36

Price Trend

价格趋势

Short

短裤

Medium

中等

Long

长时间

Overview

概述

Market News and Data brought to you by Benzinga APIs

由Benzinga API提供的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

© 2025 Benzinga.com. Benzinga 不提供投资建议。保留所有权利。